Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
A recent academic case study, published on April 22, examined using Amgen Inc's (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis.
最近發表於4月22日的一項學術案例研究，研究了使用安進公司（納斯達克股票代碼：AMGN）Blincyto（一種雙特異性CD3xCD19 T細胞結合劑）來治療嚴重的系統性硬化症患者。
The findings have implications for Cullinan Therapeutics Inc's (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager.
這些發現對庫裏南療法公司（納斯達克股票代碼：CGEM）的 CLN-978 產生了影響，後者是一種類似的CD19xCD3雙特異性T細胞參與者。
Most recently, Cullinan Therapeutics, formerly Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication.
最近，Cullinan Therapeutics（前身爲庫裏南腫瘤學）宣佈計劃擴展到自身免疫性疾病，並打算繼續在自身免疫性疾病中開發 CLN-978，將系統性紅斑狼瘡（SLE）作爲第一適應症。
William Blair notes that the case report demonstrates that Blincyto effectively treated a patient with severe systemic sclerosis, leading to rapid B-cell depletion and symptom improvement without increasing infection risk or affecting antibody levels.
威廉·布萊爾指出，病例報告表明，Blincyto有效地治療了嚴重的系統性硬化症患者，在不增加感染風險或影響抗體水平的情況下，可以快速消耗B細胞並改善症狀。
This suggests the potential for using B-cell-depleting therapy in autoimmune diseases like systemic lupus erythematosus (SLE), offering easier administration than CAR-T therapy.
這表明有可能在系統性紅斑狼瘡（SLE）等自身免疫性疾病中使用B細胞消耗療法，比CAR-T療法更易於給藥。
CLN-978's development will initially target SLE, with Phase 1 submission planned for the third quarter.
CLN-978 的開發最初將以系統性紅斑狼瘡爲目標，第一階段計劃在第三季度提交。
William Blair rates Cullinan shares Outperform based on the significant potential of CLN-619 for endometrial and cervical cancer, zipalertinib for exon 20 mutant lung cancer, CLN-049 for leukemia, and CLN-978 for autoimmune diseases.
威廉·布萊爾將庫裏南股票評爲跑贏大盤，其依據是 CLN-619 對子宮內膜癌和宮頸癌的巨大潛力，齊帕勒替尼治療外顯子 20 突變肺癌，CLN-049 用於白血病，CLN-978 用於自身免疫性疾病。
They believe the fair value of each share is $33.
他們認爲每股的公允價值爲33美元。
Updated data for CLN-619, expected in the second quarter of 2024, will be a key catalyst for the company, along with updates for CLN-978 in lupus and other autoimmune indications.
預計將在2024年第二季度發佈的 CLN-619 更新數據以及狼瘡和其他自身免疫適應症中 CLN-978 的最新數據將成爲該公司的關鍵催化劑。
The development of Cullinan's other early-stage oncology assets would provide additional upside.
庫裏南其他早期腫瘤學資產的開發將提供額外的上升空間。
Earlier Wednesday, Cullinan Therapeutics announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology.
週三早些時候，Cullinan Therapeutics宣佈，其針對晚期實體瘤患者的 CLN-619 1期試驗的臨床數據將在2024年美國臨床腫瘤學會上公佈。
The data will include the first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose-escalation cohort in patients with advanced solid tumors.
這些數據將包括 CLN-619 與檢查點抑制劑pembrolizumab聯合使用劑量遞增隊列的初步結果，以及晚期實體瘤患者單一療法劑量遞增隊列的最新結果。
Price Action: CGEM shares are up 15.10% at $19.18 at the last check Wednesday.
價格走勢：在週三的最後一次檢查中，CGEM股價上漲15.10％，至19.18美元。
Photo via PublicDomainPictures from Pixabay
照片通過 來自 Pixabay 的公共域名圖片
譯文內容由第三人軟體翻譯。